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Abstract: Background: The association between markers of inflammation (interleukin (IL)-6 and
IL-10), monocyte activation (sCD163 and sCD14), and microbial translocation (lipopolysaccharide
(LPS) and LPS binding protein) and liver fibrosis in patients with alcohol use disorder (AUD) and
no overt liver disease is not well established. Methods: We studied patients admitted for treatment
of AUD at two hospitals in Barcelona. Advanced liver fibrosis (ALF) was defined as FIB-4 > 3.25.
Results: A total of 353 participants (76.3% male) were included and 94 (26.5%) had ALF. In adjusted
correlation analyses, sCD163, sCD14, IL-6, IL-10, and LPS binding protein levels directly correlated
with FIB-4 values (adjusted correlation coefficients 0.214, 0.452, 0.317, 0.204, and 0.171, respectively).
However, LPS levels were inversely associated with FIB-4 (−0.283). All plasma marker levels in the
highest quartile, except LPS, were associated with ALF (sCD163, sCD14, IL-6, IL-10, and LPS binding
protein: adjusted odds ratio (aOR) 11.49 (95% confidence interval 6.42–20.56), 1.87 (1.11–3.16), 2.99
(1.79–5.01), 1.84 (1.11–3.16), and 2.13 (1.30–3.50), respectively). Conversely, LPS levels in the lowest
quartile were associated with ALF (aOR 2.58 (1.48–4.58), p < 0.01). Conclusion: In AUD patients,
plasma levels of the markers of inflammation, monocyte activation, and microbial translocation are
associated with ALF.
Keywords: alcohol use disorder; monocyte activation; inflammation; microbial translocation; liver fibrosis
1. Introduction
Alcohol-related liver disease is the most frequent alcohol-related chronic medical
problem and alcohol use is a major culprit of the global increase in liver-related deaths [1].
Alcohol use promotes microbial translocation due to changes in the microbiome and
increased intestinal permeability, leading to systemic inflammation, monocyte activation,
and progression of liver disease [2]. However, only a few of those who drink heavily
eventually develop end-stage liver disease [3]. The early diagnosis of subjacent liver
disease in otherwise healthy patients with AUD is intriguing [4] and there is an interest in
obtaining markers to better stratify the risk of progressive liver injury among patients with
unhealthy alcohol use [5].
All of the aforementioned pathological features (intestinal permeability, microbial
translocation, systemic inflammation, and monocyte activation) have been thoroughly
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studied in patients with overt end-stage liver disease or severe alcoholic hepatitis [6–9],
but they have been far less frequently assessed in patients with AUD without end-stage
liver disease admitted for hospital treatment of the disorder [10,11].
Systemic inflammation can be measured via the plasma levels of interleukin (IL)-6
and IL-10. In addition, sCD14 and sCD163 are markers of monocyte activation [2], with
sCD14 levels representing monocyte activation dependent on lipopolysaccharide (LPS).
The binding of LPS to LPS binding protein (LBP) is a facilitator of the union of that complex
to sCD14 and further activation of toll-like receptor 4 [2]. Increased levels of sCD163 are
consistent with monocyte activation derived not only from the presence of LPS in peripheral
blood but also from the presence of other damage-associated molecular patterns (DAMPs)
that are produced by alcohol metabolism and increased iron deposition [11]. DAMPs
trigger sterile inflammation and the activation of monocyte toll-like receptors, which
subsequently activate quiescent stellate cells, leading to progressive liver fibrosis [12]. LPS
and LBP levels are markers of microbial translocation that have been thoroughly studied
in patients with cirrhosis of the liver [13] and in those with HIV infection with or without
HCV co-infection [14,15]. However, they have been less frequently measured in patients
admitted for the treatment of AUD [9,16].
Liver fibrosis is the main predictor of the progression to cirrhosis of the liver in
patients with unhealthy alcohol use [17]. Despite liver biopsy being considered the gold
standard for the evaluation of liver fibrosis, it is an invasive and costly procedure [18] and
its performance is unlikely in patients with active alcohol or other drug use [19]. FIB-4 is a
non-invasive index for estimating liver fibrosis that includes laboratory parameters that are
usually monitored in everyday clinical practice [20]. It is a useful index for estimating liver
fibrosis in patients with an alcohol or substance use disorder who rarely undergo a liver
biopsy [19]. In addition to estimating the presence of liver fibrosis, FIB-4 also accurately
predicts mortality and other poor health outcomes in other subsets of patients, such as
incident heart failure [21].
The association between markers of inflammation and non-invasive measures of
liver fibrosis has been previously studied [22], and markers of inflammation (e.g., IL-6)
can predict the presence of advanced liver fibrosis (ALF) in HIV-infected patients [23].
However, whether markers of monocyte activation, intestinal permeability, and microbial
translocation are associated with FIB-4 values consistent with ALF in patients with an AUD
and no apparent end-stage liver disease remains to be elucidated.
We hypothesized that plasma levels of markers of monocyte activation (sCD163 and
sCD14), inflammation (IL-6 and Il-10, and microbial translocation (lipopolysaccharide (LPS)
and LPS binding protein (LBP)) are associated with FIB-4 levels in patients with AUD
without overt end-stage liver disease admitted to hospital for the treatment of the disorder.
2. Materials and Methods
2.1. Participants
We included patients admitted for hospital alcohol detoxification at two tertiary
teaching hospitals in Barcelona, Spain (Hospital Universitari Germans Trias i Pujol and
Hospital Universitari de Bellvitge) between 2013 and 2019.
Patients were referred for hospital detoxification if they were deemed ineligible for
ambulatory detoxification by addiction physicians. The main reasons for referring pa-
tients included a high risk of severe alcohol withdrawal, the presence of severe medical
co-morbidities, and poor adherence to outpatient treatment and/or unsuccessful out-
patient detoxification. Patients were excluded from the present study if they harbored
autoimmune diseases, acute and decompensated medical co-morbidities, or severe mental
health problems.
This study was approved by the Ethics Committee of both participant hospitals. Writ-
ten consent was provided by all patients before study entry and participation. This study
was conducted with compliance with ethical standards as well as the principles of good
clinical practice defined by the World Medical Association’s Declaration of Helsinki [24].
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2.2. Measurements
On the day of admission, all participants underwent a thorough physical examination
and an interview regarding their history of alcohol consumption as well as their use of
tobacco and other drugs. On the following day, blood was drawn to assess hematological
and biochemical parameters and HCV infection. Additional information regarding the
admission protocol and the methods for the detection of HCV infection as well as the
measure of sCD163, sCD14, and IL-6 has been previously published [11,19,25].
Of note, the upper limit of detection for sCD163 was 1000 ng/mL and, for all assays
above that threshold, a value of 1000 ng/m was set for the statistical analysis. IL-10
was determined by the same method as IL-6 [11] and the lower limit of detection was
0.02 pg/mL. For assays with an IL-10 concentration below the detection threshold, a value
of 0.02 pg/mL was set for the analysis.
Plasma concentrations of LPS and LBP were determined by enzyme-linked im-
munosorbent assays. Each sample was diluted 10×. Plasma concentrations of LPS and
LBP were measured in duplicate using the LPS ELISA kit (abx517692, Cambridge, UK)
and the LBP ELISA kit (abx575210, Abbexa, Cambridge, UK), respectively. All assays were
performed according to the manufacturer’s instructions. The inter-assay and intra-assay
coefficients of variation were <10% for all analyses.
Liver fibrosis was assessed by the FIB-4 index [20]: age × AST (U/L)/platelet count
(109/L) × ALT (U/L)1/2. ALF was defined as FIB-4 > 3.25.
2.3. Statistical Analysis
Descriptive statistics were expressed as the median and interquartile range (IQR) for
quantitative variables, or as absolute frequencies and percentages for qualitative variables.
We performed the chi-squared test to explore significant differences in qualitative variables
and the t-test for the mean differences in quantitative variables between participants that
had ALF measured with FIB-4 and those who did not.
We performed an unadjusted correlation analysis between plasma marker levels and
FIB-4 values as a continuous variable. In addition, we performed an adjusted correlation
analysis where all correlations were adjusted for sex, alcohol intake, and the presence of
HCV infection. We also performed logistic regression analyses to detect the association
between plasma marker levels in the highest quartile and the presence of ALF measured
with FIB-4. Finally, we performed a logistic regression analysis to detect the association
between LPS levels in the lowest quartile and the presence of ALF. All logistic regression
analyses were adjusted for sex, alcohol intake, and the presence HCV infection. The test
results were considered significant if the resulting one-tailed p-value was < 0.05. Statistical
analyses were performed using SPSS software version 15.0.1 (SPSS, Chicago, IL, USA).
3. Results
A total of 353 participants were included in the present study. Table 1 includes the
baseline clinical characteristics and the median values for several laboratory parameters
as well as for markers of monocyte activation (sCD163, sCD14), inflammation (IL-6 and
IL-10), and microbial translocation (LPS and LBP).
Participants with ALF had a higher alcohol intake at admission (186 vs. 161 g/day,
p < 0.05), a higher duration of AUD (22.8 vs. 17.5 years, p < 0.01), and a higher prevalence
of HCV infection (23.6 vs. 9.3%, p < 0.01). As seen in Table 2, patients with ALF had
higher mean sCD163 (944 vs. 638 ng/mL, p < 0.01), sCD14 (1.9 × 106 vs. 1.7 × 106 pg/mL,
p < 0.01), LBP (55 vs. 35.4 pg/mL, p = 0.04), IL-6 (16.9 vs. 5.9 pg/mL, p = 0.04), and IL-10
(2.5 vs. 1.4 pg/mL, p < 0.01) levels and lower mean LPS values (1272 vs. 1975 pg/mL,
p = 0.02).
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Table 1. Characteristics of the patients with alcohol use disorder admitted for hospital treatment.
Characteristic n = 353
Men 271 (76.7)
Age (years) 50 (43–57)
BMI (kg/m2) 25.6 (22.6–29.2)
Alcohol consumption (g/day) 140 (100–224)
Duration of AUD (years) 20 (10–25)
HCV infection 44 (12.5)
Glucose (mg/dL) 92 (84.3–102.8)
Bilirubin (mg/dL) 0.67 (0.47–1.11)
AST (U/L) 39 (23–75)
ALT (U/L) 29 (18–50)
GGT (U/L) 93 (37–288.5)
Alkaline phosphatase (U/L) 79 (59–106.5)
Creatinine (mg/dL) 0.77 (0.65–0.89)
C-reactive protein (mg/L) 2.5 (0.9–5.9)
Leukocyte count (109/L) 6.4 (5.0–7.6)
Monocyte count (109/L) 0.60 (4.85–7.75)
Hemoglobin (g/dL) 14 (12.7–15.2)
Median corpuscular volume (fl) 94.7 (90.9–99)
Platelet count (109/L) 191 (137–242)
Fibrinogen (mg/dL) 329 (269–388)
Erythrocyte sedimentation rate (mm) 12 (5–27)
Ferritin (ng/mL) 185.75 (81.25–386.83)
FIB-4 1.92 (1.07–3.69)
Advanced liver fibrosis (FIB-4 > 3.25) 94 (27.4)
sCD163 (ng/mL) 763 (476–1000)
sCD14 (×106 pg/mL) 1.65 (1.29–1.97)
IL-6 (pg/mL) 3.31 (0.87–8.16)
IL-10 (pg/mL) 0.63 (0.02–2.30)
LPS (pg/mL) 1075 (410–2282)
LBP (pg/mL) 20 (10.5–44.8)
Values are given as n (%) or median (IQR). HCV: hepatitis C virus; LPS: lipopolysaccharide; LBP: lipopolysaccha-
ride binding protein.
Table 2. Mean plasma marker values stratified by the presence of advanced liver fibrosis.
No ALF ALF p-Value
sCD163 (ng/mL) 638 (256) 944 (130) <0.01
sCD14 (×106 pg/mL) 1.7 (0.5) 1.9 (0.5) <0.01
IL-6 (pg/mL) 5.9 (13.9) 16.9 (48.0) 0.04
IL-10 (pg/mL) 1.4 (3.2) 2.5 (3.3) <0.01
LPS (pg/mL) 1975 (2217) 1272 (2071) 0.02
LBP (pg/mL) 35.4 (46.0) 55 (71.3) <0.01
LPS: lipopolysaccharide; LBP: lipopolysaccharide binding protein; ALF: advanced liver fibrosis.
In addition, we performed correlation analyses between the different marker levels
and FIB-4 levels as a continuous variable. The unadjusted correlation plots are seen in
Figure 1.
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a Adjusted for sex, alcohol intake (g/day), and HCV infection. LBP: lipopolysaccharide binding protein. Each
row represents a different model.
Finally, we performed adjusted logistic regression analyses to assess the association
between plasma marker levels in the highest quartile and the presence of ALF. All analyses
were adjusted by sex, alcohol consumption, and the presence of HCV infection. As seen in
Table 4, plasma levels of all markers, except LPS, in the highest quartile were significantly
associated with the presence of ALF with an adjusted odds ratio ranging from 1.84 for
IL-10 to 11.49 for sCD163. Conversely, LPS levels in the lowest quartile were significantly
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associated with the presence of ALF (adjusted odds ratio 2.58 (95% confidence interval:
1.48–4.58), p < 0.01).
Table 4. Logistic regression for the association between marker levels in the highest quartile and
advanced liver fibrosis.
Adjusted Odds Ratio (95% Confidence Interval) a p-Value
sCD163 11.49 (6.42–20.56) <0.01
sCD14 1.87 (1.11–3.16) 0.02
IL-6 2.99 (1.79–5.01) <0.01
IL-10 1.84 (1.11–3.16) 0.02
LPS 1.09 (0.66–1.79) 0.74
LBP 2.13 (1.30–3.50) <0.01
The highest quartile was compared with all other values. Each row represents a different model. a Adjusted for
sex, alcohol intake, and HCV infection.
4. Discussion
In this series of AUD patients with no decompensated liver disease admitted for
hospital treatment of the disorder, plasma marker levels consistent with increased monocyte
activation and increased systemic inflammation were associated with the presence of ALF,
as were higher LBP levels.
In particular, levels of IL-6, IL-10, sCD14, sCD163, and LBP in the highest quartile
and levels of LPS in the lowest quartile were associated with ALF measured with FIB-4.
The same associations were found when marker levels were correlated with FIB-4 as
a continuous variable; IL-10, sCD14, sCD163, and LBP levels directly correlated with
FIB-4 values whereas the LPS levels negatively correlated with FIB-4. All analyses that
detected these associations were adjusted by sex, amount of alcohol consumption before
admission, and the presence of HCV infection. Notably, in this study population, patients
with ALF had a greater alcohol consumption before admission and a higher prevalence of
HCV infection.
As mentioned previously, LPS levels negatively correlated with FIB-4 values and
LPS levels in the lowest quartile were associated with higher odds of ALF. These findings
suggest that higher levels of LPS may be indicative of microbial translocation occurring in
an earlier phase of the pathogenesis of alcohol-related liver disease when patients have
not yet developed significant liver fibrosis. Monocyte activation, inflammation, and higher
levels of LBP would be more prominent pathological features in later stages of the disease,
which is why all those markers were associated with higher FIB-4 values and with higher
odds of FIB-4 values suggestive of the presence of ALF.
The association between IL-6 levels and ALF has been previously described in a
cohort of HIV-infected patients with unhealthy alcohol use [23] and in other cohorts of
HIV-infected patients [26]. However, prior studies failed to detect an association between
IL-10 levels and non-invasive markers of liver fibrosis [23]. The association between
inflammatory markers and liver fibrosis is of interest as both higher IL-6 levels and FIB-4
values consistent with ALF have been associated with higher mortality and other health
outcomes in different settings [27–29].
Other authors have shown that markers of monocyte activation, especially sCD14,
have also been associated with mortality and other health complications [30,31]. In a
study performed on HIV-infected patients, Sandler and colleagues showed that sCD14
levels correlated with AST and ferritin levels, which the authors found to be suggestive of
liver inflammation [32]. In that same study, sCD4 levels correlated with gamma-glutamyl
transpeptidase, alkaline phosphatase, and alpha-fetoprotein, which the authors found to be
suggestive of liver fibrosis [32]. In a prior study by our group, sCD14 levels in the higher
quartile were associated with AST levels whereas sCD163 values in the highest quartile
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were associated with AST and bilirubin levels and the presence of HCV infection, which
suggests the presence of underlying a liver injury [11]. We are not aware of another study
that has studied the association of plasma markers of monocyte activation and intestinal
permeability and ALF in patients with AUD.
LPS levels have been studied in patients with AUD and seem to decrease with alcohol
abstinence [9,33]. LBP levels are associated with mortality in patients with decompensated
cirrhosis [34] and appear to decrease with the use of beta-blockers in patients with portal
hypertension [13] but the levels in patients with AUD without overt liver disease have
not received much attention in the literature. Our findings support the use of LBP as a
surrogate marker of microbial translocation in patients with AUD. In addition, no other
studies have evaluated the association between LPS and LBP levels and ALF.
Importantly, our findings underscore that monocyte activation, systemic inflammation,
and microbial translocation are present in patients with AUD but without end-stage liver
disease and admitted for hospital treatment, and that these levels are associated with
FIB-4 values and the presence of ALF assessed with non-invasive measures. Patients with
FIB-4 values suggestive of ALF should be prioritized to receive more intensive forms of
follow-up treatment to secure alcohol abstinence. Abstinence from alcohol is associated
with increased survival even in patients who already present with advanced forms of
alcohol-related liver disease [3].
This study has a few limitations to be noted. First, plasma markers were assessed on
the second day of hospital admission and their levels may be modified by alcohol absti-
nence. A sequential measurement of these markers during hospital alcohol detoxification is
a potential future line of inquiry. Second, we included patients with the most severe forms
of AUD (i.e., a 20-year history of the disorder and a median daily alcohol intake upon
admission of 140 g/day) and our findings may not be extrapolated to patients with milder
forms of unhealthy alcohol use as seen in primary care or hepatology clinics. Third, we es-
timated liver fibrosis with FIB-4, which has not been validated against the gold standard of
liver biopsy for alcohol-related liver disease [35]. Despite that few authors have expressed
concerns about the accuracy of FIB-4 [36], the European Association for the Study of the
Liver has recently published an updated version of their guideline for the non-invasive
diagnosis of a liver injury and recommends the use of FIB-4 as a first-line method for detect-
ing patients with high probability of presenting significant liver disease [37]. The present
study adds to the literature that categorizes FIB-4 as a reliable tool for estimating liver
fibrosis in patients in whom the performance of a liver biopsy is unlikely [38]. In addition,
FIB-4 includes variables that are routinely assessed in the everyday care of subjects with
liver disease and is an ideal method of estimating liver fibrosis in resource-limited settings
where the use of transient elastography is prohibitive. In addition to being a reliable
predictor of mortality [29], FIB-4 values are associated with important disease correlates in
this case series of patients with an AUD admitted for hospital treatment for the disorder.
In summary, the present study shows that higher levels of markers of inflammation,
monocyte activation, and LBP and lower levels of LPS are associated with FIB-4 values as
well as with ALF in patients admitted for the treatment of AUD.
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